<DOC>
	<DOCNO>NCT01076322</DOCNO>
	<brief_summary>This open-label , randomize , cross-over , active-controlled study evaluate efficacy safety effect use Meptin® Swinghaler Ventolin® MDI stable asthma patient .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Meptin® Swinghaler® Ventolin® MDI Stable Asthma Patients</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Procaterol</mesh_term>
	<criteria>1 . Male female outpatient age ≥ 16 year old stable mild moderate persistent asthma ; Stability assess patient remain severity class ( mild , moderate ) acute exacerbation investigator judgment past 14 day ; 2 . Pulmonary function test : Improvement ≥12 % reversibility FEV1 FVC follow administration inhale β2agonist study ; Positive result Bronchoprovocation test ( PC20 ≤ 32 mg/ml ) study . 3 . Baseline force expiratory volume one second 60 % ≤ ( FEV1 ) ≤ 90 % predict value entry study ; 1 . Hypersensitivity β2agonist lactose ; 2 . Hospitalization due asthma previous 3months ; 3 . Respiratory tract infection require treatment antibiotic previous 4 week ; 4 . Oral systemic corticosteroid previous 4weeks ; 5 . Inadequately controlled hyperthyroidism ; 6 . Severe hepatic renal cardiovascular disease judge investigator ; 7 . Patients receive investigational drug within 30 day prior admission study ; 8 . Patients significant alcohol , drug medication abuse judged investigator ; 9 . Females pregnant breastfeeding ; ( exception : Females childbearing age might include , opinion investigator , use adequate contraceptive precaution ) .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>